Screener
Syndax Pharmaceuticals SNDX Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest income | 3,561 | 7,183 |
| Other expense | (186) | (221) |
| Total other (expense) income, net | (8,471) | (1,089) |
| Net loss | $(42,673) | $(84,846) |
| Other Comprehensive loss: | ||
| Unrealized (loss) gain on marketable securities | (441) | 364 |
| Other Comprehensive loss | (43,114) | (84,482) |
| Net loss per share: |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's net income?
- Syndax Pharmaceuticals (SNDX) reported net income of -$42.67M in Q1 2026.
- How has Syndax Pharmaceuticals's net income changed year-over-year?
- Syndax Pharmaceuticals's net income increased by 49.7% year-over-year, from -$84.85M to -$42.67M.
- What is the long-term trend for Syndax Pharmaceuticals's net income?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's net income has grown at a 84.0% compound annual growth rate (CAGR), from $24.93M to -$285.42M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Syndax Pharmaceuticals's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude